The company said, “Fourth quarter and full year 2023 revenue and Adjusted Revenue1,2 is expected to exceed the November guidance range. Fourth quarter revenue and Adjusted Revenue1,2 is expected to be in the range of approximately $195 million to $197 million, an increase of approximately 6% to 7% year-over-year.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX:
- ‘Profitability Is the Key’: Barclays Says These 3 Health Tech Stocks Are Poised for Growth
- Barclays starts healthcare technology, distribution with Neutral view
- GoodRx initiated with an Overweight at Barclays
- GoodRx (NASDAQ:GDRX) Turns Bad after Stock Downgrade
- GoodRx downgraded to Underperform from Buy at BofA